| Assay ID | Title | Year | Journal | Article |
|---|
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | | | |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID93939 | The compound was tested in vitro for growth of inhibitory activity against lymphoid leukemia L1210 cells | 1989 | Journal of medicinal chemistry, Oct, Volume: 32, Issue:10
| New anticancer agents: alterations of the carbamate group of ethyl (5-amino-1,2-dihydro-3-phenylpyrido[3,4-b]pyrazin-7-yl)car bamates. |
| AID131669 | Increase in life span (ILS) in mice implanted intraperitoneally with lymphocytic leukemia P388 cells at a nontoxic dose of 2 mg/kg | 1990 | Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
| Antimitotic agents: synthesis of imidazo[4,5-c]pyridin-6-ylcarbamates and imidazo[4,5-b]pyridin-5-ylcarbamates. |
| AID98840 | Fraction of the cell population of cultured lymphoid leukemia L1210 cells in mitosis after 24 hr at the concentration of 0.3 uM | 1983 | Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
| 1,2-Dihydropyrido[3,4-b]pyrazines: structure-activity relationships. |
| AID131672 | Increase in life span at the highest nontoxic dose against P-388 tumor cell after 1 day at 12.5 mg/kg | 1982 | Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
| New anticancer agents: synthesis of 1,2-dihydropyrido[3,4-b]pyrazines (1-deaza-7,8-dihydropteridines). |
| AID98511 | Cytotoxicity against lymphoid leukemia L1210 cells | 1991 | Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
| Antimitotic agents. Alterations at the 2,3-positions of ethyl (5-amino-1,2-dihydropyrido[3,4-b]pyrazin-7-yl)carbamates. |
| AID98557 | Concentration required to inhibit 50% proliferation of cultured lymphoid leukemia L1210 cells was measured | 1990 | Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
| Potential antimitotic agents. Synthesis of some ethyl benzopyrazin-7-ylcarbamates, ethyl pyrido[3,4-b]pyrazin-7-ylcarbamates, and ethyl pyrido[3,4-e]-as-triazin-7-ylcarbamates. |
| AID154002 | antitumor activity against lymphocyte leukemia P388 in mice as percentage of increase in life span for 1-9 days schedule. (values in the parenthesen indicates dose) | 1983 | Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
| 1,2-Dihydropyrido[3,4-b]pyrazines: structure-activity relationships. |
| AID131826 | Increase in life span at the highest nontoxic dose against P-388 tumor cell after 1-9 days at 2 mg/kg | 1982 | Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
| New anticancer agents: synthesis of 1,2-dihydropyrido[3,4-b]pyrazines (1-deaza-7,8-dihydropteridines). |
| AID115195 | Increase in the life span(ILS) of mice. | 1991 | Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
| Antimitotic agents. Alterations at the 2,3-positions of ethyl (5-amino-1,2-dihydropyrido[3,4-b]pyrazin-7-yl)carbamates. |
| AID153998 | antitumor activity against lymphocyte leukemia P388 in mice as percentage of increase in life span for 1 day schedule | 1983 | Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
| 1,2-Dihydropyrido[3,4-b]pyrazines: structure-activity relationships. |
| AID96774 | Fraction of cell population of cultured lymphoid leukemia L1210 cells in mitosis at a dose of 0.3 uM after 24 hr | 1982 | Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
| New anticancer agents: synthesis of 1,2-dihydropyrido[3,4-b]pyrazines (1-deaza-7,8-dihydropteridines). |
| AID98837 | Fraction of the cell population of cultured lymphoid leukemia L1210 cells in mitosis after 12 hr at the concentration of 0.03 uM | 1983 | Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
| 1,2-Dihydropyrido[3,4-b]pyrazines: structure-activity relationships. |
| AID152555 | Antitumor activity in mice implanted with lymphocytic P388 cells after intraperitoneal administration. | 1991 | Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
| Antimitotic agents. Alterations at the 2,3-positions of ethyl (5-amino-1,2-dihydropyrido[3,4-b]pyrazin-7-yl)carbamates. |
| AID153568 | Increase in the life span of mice implanted with lymphocytic leukemia P388 at the highest nontoxic dose of 2 mg/Kg given to the compound intraperitoneally | 1989 | Journal of medicinal chemistry, Oct, Volume: 32, Issue:10
| New anticancer agents: alterations of the carbamate group of ethyl (5-amino-1,2-dihydro-3-phenylpyrido[3,4-b]pyrazin-7-yl)car bamates. |
| AID96769 | Fraction of cell population of cultured lymphoid leukemia L1210 cells in mitosis at a dose of 0.03 uM after 12 hr | 1982 | Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
| New anticancer agents: synthesis of 1,2-dihydropyrido[3,4-b]pyrazines (1-deaza-7,8-dihydropteridines). |
| AID96600 | Concentration that causes a mitotic index (number of cells in mitosis divided by total cells) of cultured lymphoid leukemia L1210 cells. | 1990 | Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
| Antimitotic agents: synthesis of imidazo[4,5-c]pyridin-6-ylcarbamates and imidazo[4,5-b]pyridin-5-ylcarbamates. |
| AID94097 | Mitotic index (fraction of cells in mitosis divided by total cells ) for cultured lymphoid leukemia L1210 cells | 1989 | Journal of medicinal chemistry, Oct, Volume: 32, Issue:10
| New anticancer agents: alterations of the carbamate group of ethyl (5-amino-1,2-dihydro-3-phenylpyrido[3,4-b]pyrazin-7-yl)car bamates. |
| AID131829 | Increase in life span at the highest nontoxic dose against Vincristine-resistant line of P-388 tumor cell after 1 day at 12 mg/kg | 1982 | Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
| New anticancer agents: synthesis of 1,2-dihydropyrido[3,4-b]pyrazines (1-deaza-7,8-dihydropteridines). |
| AID98350 | Inhibitory activity against lymphoid leukemia L1210 cells | 1989 | Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
| New anticancer agents: chiral isomers of ethyl 5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazine-7-car bamate . |
| AID221350 | Concentration that causes a mitotic index of 0.5 for cultured lymphoid leukemia L1210 cells was determined | 1990 | Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
| Potential antimitotic agents. Synthesis of some ethyl benzopyrazin-7-ylcarbamates, ethyl pyrido[3,4-b]pyrazin-7-ylcarbamates, and ethyl pyrido[3,4-e]-as-triazin-7-ylcarbamates. |
| AID154913 | Increase in the life span of mice with P388 leukemia after the administration of the highest non toxic dose (2 mg/kg) | 1989 | Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
| New anticancer agents: chiral isomers of ethyl 5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazine-7-car bamate . |
| AID98692 | Inhibitory concentration against proliferation of cultured lymphoid leukemia L1210 cells during 48 hrs. | 1982 | Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
| New anticancer agents: synthesis of 1,2-dihydropyrido[3,4-b]pyrazines (1-deaza-7,8-dihydropteridines). |
| AID96602 | Antimitotic activity against lymphoid leukemia L1210 cells. | 1991 | Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
| Antimitotic agents. Alterations at the 2,3-positions of ethyl (5-amino-1,2-dihydropyrido[3,4-b]pyrazin-7-yl)carbamates. |
| AID96951 | inhibition of proliferation of cultured lymphoid leukemia L1210 cells during 48 hr. | 1983 | Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
| 1,2-Dihydropyrido[3,4-b]pyrazines: structure-activity relationships. |
| AID98509 | The compound was tested for cell growth inhibitory activity against lymphoid leukemia L1210 cell line. | 1990 | Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
| Antimitotic agents: synthesis of imidazo[4,5-c]pyridin-6-ylcarbamates and imidazo[4,5-b]pyridin-5-ylcarbamates. |
| AID96601 | Mitotic index (fraction of cells in mitosis divided by total cells) in cultured lymphoid leukemia L1210 cells | 1989 | Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
| New anticancer agents: chiral isomers of ethyl 5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazine-7-car bamate . |
| AID131816 | Increase in life span at the highest nontoxic dose against P-388 tumor cell after 1,5,9 days at 4.5 mg/kg | 1982 | Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
| New anticancer agents: synthesis of 1,2-dihydropyrido[3,4-b]pyrazines (1-deaza-7,8-dihydropteridines). |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |